Zeitschrift für Gastroenterologie

LinksSchließen

Referenz

Schmiegel WH, Reinacher-Schick A, Freier W et al.
Comparable safety and response rate with bevacizumab in combination with capecitabine/oxaliplatin (CapOx/Bev) versus capecitabine/irinotecan (CapIri/Bev) in advanced CRC (mCRC): A randomized phase II study of the AIO GI tumor study group.

Journal of Clinical Oncology 2007; ASCO Annual Meeting Proceedings Part I 2007
25 (Suppl. 18) 4034

Bibliographische Angaben herunterladen

Suchen in: